Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C. Itzykson R, et al. Among authors: fasan a. Blood. 2018 Jul 12;132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24. Blood. 2018. PMID: 29692343 Free article.
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M. Elena C, et al. Among authors: fasan a. Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030. Epub 2016 Jul 6. Blood. 2016. PMID: 27385790 Free PMC article.
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S. Weber S, et al. Among authors: fasan a. Blood Cancer J. 2014 Jan 10;4(1):e173. doi: 10.1038/bcj.2013.71. Blood Cancer J. 2014. PMID: 24413067 Free PMC article.
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S. Grossmann V, et al. Among authors: fasan a. Br J Haematol. 2013 Jun;161(5):649-658. doi: 10.1111/bjh.12297. Epub 2013 Mar 25. Br J Haematol. 2013. PMID: 23521373 Free article.
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Weissmann S, et al. Among authors: fasan a. Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25. Leukemia. 2012. PMID: 22116554
The role of different genetic subtypes of CEBPA mutated AML.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. Fasan A, et al. Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23. Leukemia. 2014. PMID: 24056881
28 results